| Assessment Status | Rapid Review complete |
| HTA ID | 24037 |
| Drug | Aztreonam-avibactam |
| Brand | Emblaveo® |
| Indication | For the treatment of the following infections in adult patients: • Complicated intra-abdominal infection (cIAI) • Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritis. Aztreonam-avibactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. |
| Assessment Process | |
| Rapid review commissioned | 23/09/2024 |
| Rapid review completed | 25/10/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that aztreonam-avibactam not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
